Cite
Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer.
MLA
Lu, Qianyi, et al. “Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer.” Oncologist, vol. 25, no. 1, Jan. 2020, p. 21. EBSCOhost, https://doi.org/10.1634/theoncologist.2019-0564.
APA
Lu, Q., Xia, W., Lee, K., Zhang, J., Yuan, H., Yuan, Z., Shi, Y., Wang, S., & Xu, F. (2020). Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer. Oncologist, 25(1), 21. https://doi.org/10.1634/theoncologist.2019-0564
Chicago
Lu, Qianyi, Wen Xia, Kaping Lee, Jingmin Zhang, Huimin Yuan, Zhongyu Yuan, Yanxia Shi, Shusen Wang, and Fei Xu. 2020. “Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer.” Oncologist 25 (1): 21. doi:10.1634/theoncologist.2019-0564.